Obesity, overweight at diagnosis ups B-cell lymphoma prognosis

May 30, 2012
Obesity, overweight at diagnosis ups B-Cell lymphoma prognosis
For U.S. veterans with diffuse large B-cell lymphoma, being overweight or obese at time of diagnosis correlates with improved survival, according to a study published online May 29 in the Journal of Clinical Oncology.

(HealthDay) -- For U.S. veterans with diffuse large B-cell lymphoma (DLBCL), being overweight or obese at time of diagnosis correlates with improved survival, according to a study published online May 29 in the Journal of Clinical Oncology.

To investigate the association between (BMI) at diagnosis and overall survival, Kenneth R. Carson, M.D., from the St. Louis Veterans Affairs Medical Center, and colleagues conducted a involving 2,534 U.S. veterans diagnosed with DLBCL from 1998 to 2008.

The researchers found that the mean age at diagnosis was 68 years, and 64 percent of patients were overweight or obese. Compared with other BMI groups, obese patients were significantly younger, had significantly fewer B symptoms, and showed a trend toward lower-stage disease. Compared with normal-weight patients, Cox analysis showed decreased mortality for overweight and obese patients (hazard ratios, 0.73 and 0.68, respectively). Treatment during the rituximab era attenuated the but did not impact the association between BMI and survival. One year before diagnosis, disease-related weight loss occurred in 29 percent of patients with weight data, but Cox analysis based on BMI one year before diagnosis showed a persistent association between overweight/obesity and reduced mortality risk.

"Being overweight or obese at the time of DLBCL diagnosis is associated with improved overall survival," the authors write. "Understanding the mechanisms responsible for this association will require further study."

One author disclosed a financial relationship with Genentech.

Explore further: Physician's weight may influence obesity diagnosis and care

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Physician's weight may influence obesity diagnosis and care

January 26, 2012
A patient's body mass index (BMI) may not be the only factor at play when a physician diagnoses a patient as obese. According to a new study led by researchers at the Johns Hopkins Bloomberg School of Public Health, the diagnosis ...

Lower all-Cause, cardio mortality in obese with RA

May 2, 2012
(HealthDay) -- Overweight and obese patients with rheumatoid arthritis (RA) have lower all-cause and cardiovascular mortality, but have substantially increased risks of comorbidities, medical costs, and reduced quality of ...

Recommended for you

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.